Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study

doi:10.1177/17562848231160630

科研成果详情

题名	Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study
作者	Wang, Kang 3; Liu, Zong-Han 3; Yu, Hong-Ming 3; Cheng, Yu-Qiang 3; Xiang, Yan-Jun4; Zhong, Jing-Ya 2; Ni, Qian-Zhi 3; Zhou, Li-Ping 3; Liang, Chao 5; Zhou, Hong-Kun 6; Pan, Wei-Wei 2,7; Guo, Wei-Xing 3; Shi, Jie 3; Cheng, Shu-Qun 1,2
发表日期	2023
发表期刊	Therapeutic advances in gastroenterology 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	atezolizumab bevacizumab biliary tract cancer combination therapy gemcitabine and oxaliplatin
其他关键词	OPEN-LABEL ; OXALIPLATIN ; GEMCITABINE ; CHEMOTHERAPY ; BIOMARKER ; ALS2CL
摘要	Anti-programmed cell death ligand 1/vascular endothelial growth factor inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tract cancer (BTC)., We investigated the efficacy and safety of atezolizumab, bevacizumab, and gemcitabine plus oxaliplatin (GEMOX) in advanced BTC and explore the potential biomarkers related to the response., Multicenter, single-arm, retrospective study., {AbstractText=Advanced BTC patients, who received a triple combination therapy at three medical centers between 18 March 2020 and 1 September 2021, were included. Treatment response was evaluated via mRECIST and RECIST v1.1. Endpoints included the overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. The whole exome sequencing of pathological tissues was conducted for bioinformatic analysis.}, In all, 30 patients were enrolled. The best ORR was 76.7% and the DCR was 90.0%. The median PFS was 12.0 months, and the median OS was not reached. During the treatment, 10.0% (3/30) of patients suffered from ⩾grade 3 treatment-related adverse events (TRAEs). Furthermore, fever (73.3%), neutropenia (63.3%), increased aspartate transaminase and alanine aminotransferase levels (50.0% and 43.3%, respectively) are the most common TRAEs. Bioinformatics analysis revealed patients with altered ALS2CL had a higher ORR., The triple combination of atezolizumab, bevacizumab, and GEMOX may be efficacious and safe for patients with advanced BTC. ALS2CL may be a potential predictive biomarker for the efficacy of triple combination therapy.
出版者	SAGE PUBLICATIONS LTD
ISSN	1756-283X
EISSN	1756-2848
卷号	16
DOI	10.1177/17562848231160630
页数	13
WOS类目	Gastroenterology & Hepatology
WOS研究方向	Gastroenterology & Hepatology
WOS记录号	WOS:000959734800001
收录类别	PUBMED ; SCIE
URL	查看原文
PubMed ID	37007215
通讯作者地址	[Cheng, Shu-Qun]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, 225 Changhai Rd, Shanghai 200433, Peoples R China. ; [Cheng, Shu-Qun]Jiaxing Univ, Coll Med, Dept Cell Biol, Jiaxing, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/174224
专题	附属第一医院_肝胆外科
通讯作者	Cheng, Shu-Qun
作者单位	1.Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, 225 Changhai Rd, Shanghai 200433, Peoples R China; 2.Jiaxing Univ, Coll Med, Dept Cell Biol, Jiaxing, Peoples R China; 3.Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China; 4.Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou, Peoples R China; 5.Shanghai Univ Tradit Chinese Med, Hosp Integrated Tradit Chinese & Western Med, Shanghai, Peoples R China; 6.Jiaxing Univ, Hosp Jiaxing 1, Affiliated Hosp Jiaxing Univ, Jiaxing, Peoples R China; 7.Jiaxing Univ, STI Valley Ind & Innovat Inst G60, Jiaxing, Peoples R China
推荐引用方式 GB/T 7714	Wang, Kang,Liu, Zong-Han,Yu, Hong-Ming,et al. Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study[J]. Therapeutic advances in gastroenterology,2023,16.
APA	Wang, Kang., Liu, Zong-Han., Yu, Hong-Ming., Cheng, Yu-Qiang., Xiang, Yan-Jun., ... & Cheng, Shu-Qun. (2023). Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study. Therapeutic advances in gastroenterology, 16.
MLA	Wang, Kang,et al."Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study".Therapeutic advances in gastroenterology 16(2023).